The American College of Physicians (ACP) has issued a strong call for a significant modernization of the regulatory framework governing dietary supplements, asserting that the current system, largely dictated by the Dietary Supplement Health and Education Act of 1994 (DSHEA), poses a considerable risk to public health. In a comprehensive position paper published in the prestigious Annals of Internal Medicine, the ACP outlines a series of ten recommendations aimed at bolstering oversight, enhancing safety evaluations, and improving transparency within the multi-billion dollar industry. The organization’s stance directly challenges the prevailing approach to supplement regulation, which it argues is insufficient in protecting consumers from potentially harmful products.
The ACP’s critique centers on fundamental differences in how dietary supplements are regulated compared to pharmaceuticals and even food additives. "Under the current regulatory framework, supplements are not evaluated for their safety before going to market, unlike drugs and food additives," stated Jan Carney, M.D., ACP president, underscoring a core concern. This lack of mandatory premarket safety assessment is a central tenet of the ACP’s argument, suggesting that the onus of identifying potential dangers falls too heavily on consumers and healthcare professionals after a product is already widely available.
A Growing Concern: The Scale of Supplement Use and Adverse Events
The ACP’s concerns are amplified by the widespread use of dietary supplements across the United States. According to the organization’s findings, over 50% of adults in the U.S. regularly consume dietary supplements. However, a significant disconnect exists between this widespread adoption and informed medical guidance, with only approximately 25% of supplement users reporting that their healthcare professionals recommended the specific products they are taking. This gap suggests a reliance on consumer-driven choices, often influenced by marketing and anecdotal evidence rather than robust scientific endorsement.
The potential consequences of this regulatory gap are starkly illustrated by the volume of adverse event reports submitted to the U.S. Food and Drug Administration (FDA). Between 2004 and 2021, the FDA’s Center for Food Safety and Applied Nutrition (CFSAN) received an alarming number of adverse event reports related to dietary supplement usage, totaling over 79,000. While not all reported events may be directly attributable to supplement consumption or indicate severe harm, the sheer volume raises significant questions about product safety and the effectiveness of postmarket surveillance alone.
"Although some dietary supplements, principally vitamins and minerals, are thoroughly tested for safety and efficacy… many others are not backed by strong scientific evidence or contain unsafe ingredients," the authors of the position paper noted. This highlights a critical distinction the ACP draws between well-researched supplements and those with less scientific backing, suggesting that the current regulatory umbrella fails to adequately differentiate between them.
The Pillars of ACP’s Proposed Modernization
The ACP’s ten recommendations for modernizing DSHEA are multifaceted, with several key proposals poised to have the most significant impact on the dietary supplement industry. At the forefront is the call for increased funding for regulatory agencies, enabling more robust oversight and enforcement capabilities. Beyond increased resources, the ACP advocates for a fundamental shift in the regulatory paradigm.
A primary recommendation is the establishment of a mandatory premarket safety review for dietary supplements, mirroring the rigorous processes applied to pharmaceuticals. This would require manufacturers to demonstrate the safety of their products to regulatory bodies before they can be marketed to consumers. Such a system would fundamentally alter the current landscape, where the burden of proof for a supplement’s lack of safety often falls on regulators after harm has occurred.
Furthermore, the ACP emphasizes the need for enhanced postmarket surveillance and the development of a comprehensive, publicly accessible national database for dietary supplement adverse events. This database would serve as a crucial tool for identifying emerging safety concerns and informing both healthcare professionals and consumers. The organization also calls for the integration of dietary supplement information into electronic health records (EHR) systems. This integration would empower healthcare providers with a more complete picture of their patients’ health regimens, enabling them to identify potential drug-supplement interactions or contraindications more effectively. The ACP acknowledges that physicians themselves may possess limited knowledge about the vast array of dietary supplements available, and better data integration is seen as a step toward rectifying this.
"Skewed public perception of the safety of supplements and low rates of reporting their use to physicians and other healthcare professionals only contribute to making the public more at risk for severe adverse outcomes," Carney stated, reinforcing the interconnectedness of public awareness, professional engagement, and regulatory effectiveness.
Defining "Strong Scientific Evidence" in the Supplement Realm
A crucial element of the ACP’s recommendations, and indeed any discussion around supplement efficacy, is the definition of "strong scientific evidence." The ACP clarifies its position by defining this as "peer-reviewed clinical trials demonstrating the safety and efficacy of a supplement/dietary ingredient for claims made by the manufacturer." The authors further elaborated that "peer-reviewed literature and studies related to pharmacokinetics, pharmacodynamics, and dosages of dietary ingredients are integral to informing a strong evidence base." This definition aligns closely with established scientific standards for evaluating health interventions.
This perspective resonates with industry experts who work in substantiating supplement claims. Susan Hewlings, Ph.D., co-founder at Substantiation Sciences and SVP of scientific affairs at Radicle Sciences, outlines her criteria for evaluating scientific substantiation. She emphasizes the importance of studies where the dose matches the label dose, the tested ingredient aligns with what is actually in the product, the study population accurately reflects the target demographic for the claim, and the endpoints measured are validated and correspond to the claim being made. Hewlings also stresses the necessity of appropriate statistical analyses, interpretations, and comprehensive toxicology assessments, both preclinical and in humans. "Safety evidence should go beyond an absence of reported harm," she added, indicating a need for proactive safety evaluations rather than reactive responses to adverse events. Hewlings also notes the increasing research within the industry, driven by consumer demand for transparency and the proliferation of information, particularly on social media.
Industry Responses: A Divided Landscape
The ACP’s position paper has naturally elicited strong reactions from various industry organizations, revealing a clear divide on the proposed regulatory changes. The Council for Responsible Nutrition (CRN), a prominent trade association representing dietary supplement manufacturers and ingredient suppliers, expressed a qualified agreement with the ACP’s concerns. "Where we fundamentally disagree is the paper’s conclusion that these goals require replacing DSHEA with a pharmaceutical-style premarket approval system for dietary supplements," the CRN stated in a released statement. While the CRN supports mandatory product listing, they contend that many of the issues highlighted by the ACP, such as the presence of unsafe ingredients or unsubstantiated claims, are already prohibited under existing DSHEA provisions.
"These examples do not demonstrate that DSHEA has failed; they demonstrate the need for stronger enforcement against companies that violate it," the CRN argued, advocating for enhanced enforcement of current regulations rather than a complete overhaul.
Daniel Fabricant, Ph.D., CEO and president of the Natural Products Association (NPA), characterized the ACP’s position paper as "hyperbole." He asserted that the medical community often lacks a comprehensive understanding of how the dietary supplement industry is regulated. Fabricant pointed to existing resources available to healthcare professionals, such as the National Institutes of Health’s (NIH) Dietary Supplement Label Database (DSLD), as evidence that tools for informed decision-making are already in place.
"Consumers who use supplements and engage in self-care achieve better health outcomes," Fabricant stated in an NPA release, framing dietary supplements as a vital component of a healthy lifestyle focused on nutrition and disease prevention. "Unfortunately, ACP is tone-deaf to the growing role of dietary supplements as part of a healthy lifestyle focused on nutrition and prevention of disease. NPA will continue to fiercely oppose any proposals to dismantle the strong regulatory framework under DSHEA."
Broader Implications and Future Outlook
The ACP’s strong stance and detailed recommendations signal a potential inflection point in the ongoing debate surrounding dietary supplement regulation. The organization’s influence within the medical community lends significant weight to its call for change, potentially galvanizing further discussion among policymakers and public health advocates.
The core tension lies between the industry’s emphasis on consumer choice and the established medical community’s prioritization of rigorous scientific evidence and premarket safety assurances. The ACP’s argument for a more robust regulatory framework, akin to that for pharmaceuticals, suggests a desire to elevate the standard of evidence required for supplements and to shift the burden of proof for safety and efficacy onto manufacturers.
The implications of such a shift could be far-reaching. A pharmaceutical-style premarket approval process would likely increase compliance costs for supplement manufacturers, potentially leading to consolidation within the industry and a reduction in the number of products available. For consumers, it could mean greater assurance of product safety and efficacy but potentially at the cost of accessibility and variety.
The call for integrating supplement data into EHR systems, if implemented, could revolutionize how healthcare providers approach nutritional support and identify potential risks. This would foster a more informed dialogue between patients and clinicians regarding supplement use.
As the debate continues, the ACP’s position paper serves as a critical document, highlighting the perceived vulnerabilities in the current regulatory system and proposing concrete steps toward what it views as a more responsible and health-conscious approach to dietary supplements. The industry’s strong counterarguments underscore the significant economic and philosophical differences at play, suggesting that the path toward regulatory reform will likely be a complex and contested one. The future of dietary supplement regulation in the United States hinges on finding a balance between consumer access, industry innovation, and the paramount imperative of public health protection.
